SCHEMBL3536621

SCHEMBL3536621

CCC(O)CN(CC(O)CC)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.44
LMNA P02545 1/20 0.43
KDM4E B2RXH2 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
NR1H2 P55055 1/20 0.41
NR1H3 Q13133 1/20 0.41
ALDH1A1 P00352 2/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.38
CETP P11597 2/20 0.38
AOC3 Q16853 2/20 0.38
CYP2D6 P10635 1/20 0.38
TRPA1 O75762 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11746154 0.92 TSHR (0.50) TSHRLMNAKDM4EL3MBTL1POLB
SCHEMBL11741582 0.82 USP2 (0.43) TSHRLMNAKDM4EL3MBTL1POLB
SCHEMBL11504772 0.82 KDM4E (0.45) TSHRLMNAKDM4EL3MBTL1POLB
SCHEMBL3537961 0.82 CYP2C19 (0.41) TSHRLMNANR1H2NR1H3ALDH1A1
SCHEMBL18995910 0.81 CETP (0.47) LMNAKDM4EALDH1A1GLACYP3A4
SCHEMBL8959067 0.81 KDM4E (0.44) TSHRLMNAKDM4EL3MBTL1POLB
SCHEMBL20717114 0.81 LMNA (0.45) TSHRLMNANR1H2NR1H3ALDH1A1
SCHEMBL11675994 0.81 LTA4H (0.43) LMNAKDM4EL3MBTL1POLBALDH1A1
SCHEMBL1632396 0.80 TDP1 (0.55) TSHRLMNAKDM4EL3MBTL1NR1H2
SCHEMBL18177923 0.80 TSHR (0.48) TSHRLMNAKDM4EL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812401-B1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF SE (DE) 2015-06-24 EP disclosed
US-8026295-B2 Curable acrylic mixture including a hindered amine light stabilizer having a 4-Amino-2,2,6,6-tetramethylpiperidin-1 oxyl moiety linked to an acrylic moiety so as to polymerize with the primary resin DENTSPLY INTERNATIONAL, INC. (US) 2011-09-27 US disclosed
US-8026295-B2 Curable acrylic mixture including a hindered amine light stabilizer having a 4-Amino-2,2,6,6-tetramethylpiperidin-1 oxyl moiety linked to an acrylic moiety so as to polymerize with the primary resin DENTSPLY INTERNATIONAL, INC. (US) 2011-09-27 US disclosed
US-7799920-B2 Method for producing perylene-3,4-dicarboxylic acid imides BASF AKTIENGESELLSCHAFT (DE) 2010-09-21 US disclosed
US-20080114170-A1 Method For Producing Perylene-3,4-Dicarboxylic Acid Imides BASF AKTIENGESELLSCHAFT (DE) 2008-05-15 US disclosed
US-20080103229-A1 Dental composition with improved light stability WALZ UWE 2008-05-01 US disclosed
US-20080103229-A1 Dental composition with improved light stability WALZ UWE 2008-05-01 US disclosed
EP-1812401-A1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF AKTIENGESELLSCHAFT (DE) 2007-08-01 EP disclosed
WO-2006050860-A1 METHOD FOR PRODUCING PERYLENE-3,4-DICARBOXYLIC ACID IMIDES BASF AKTIENGESELLSCHAFT (DE) 2006-05-18 WO disclosed
US-3993619-A AZO DYES BAYER AKTIENGESELLSCHAFT (DT) 1976-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103229-A1 Dental composition with improved light stability RARA, MAP1LC3A, MAP1LC3C TSHR 3729/4885LMNA 1016/4885KDM4E 2354/4885
US-20080114170-A1 Method For Producing Perylene-3,4-Dicarboxylic Acid Imides CPNE4, IDH3A, RPL23A TSHR 2288/4885LMNA 642/4885KDM4E 2062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.